Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007, 151(2):201-207 | DOI: 10.5507/bp.2007.035

NEUROHUMORAL CHANGES IN CHRONIC HEART FAILURE

Lenka Spinarova, Jiri Vitovec
1st Internal Cardioangiologic Department, Medical Faculty of Masaryk University, Pekarská 53, 656 91 Brno, Czech Republic

Background: Humoral systems play an important role in the patophysiology and development of chronic heart failure (CHF).

Methods: We conducted a search of neurohumoral activation in heart failure and its risk in the development of CHF.

Results and conclusion: Neurohumoral factors may be divided into vasoconstrictive, vasodilative and cytokines. The main vasoconstrictive systems are the renin-angiotensin-aldosterone system (RAAS) and the sympathoadrenal system (SAS). Cytokines include tumour necrosis factor (TNF) alpha and interleukins. The systems of actions are interconnected and they mutually influence their secretion and activities. The possibilities of their detection and assessment for clinical purposes depend on their changes and kinetics in the organism and on the activity of individual metabolites. Apart from their vasoactive effects, the majority of humoral actions also interfere in the process of remodelling, function of the endothelium, blood elements, cardiomyocytes, cells of the smooth muscles, and in immunity as well as inflammatory processes. The rapid development of knowledge on the humoral actions in recent years has made possible their utilisation in diagnostics, treatment and prognosis.

Keywords: Heart failure, Humoral activation, Cytokines

Received: September 10, 2007; Accepted: October 30, 2007; Published: December 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Spinarova, L., & Vitovec, J. (2007). NEUROHUMORAL CHANGES IN CHRONIC HEART FAILURE. Biomedical papers, 151(2), 201-207. doi: 10.5507/bp.2007.035
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Stejfa M, a kol. Kardiologie (treti, prepracovane a doplnene vydani). Grada Publishing a. 2007, s 722
    2. Widimský J. Srdeční selhání, 2. roząířené a přepracované vydání, Triton 2003, s 556
    3. ©pinar J, Vítovec J. Chronické srdeční selhání, Medica s. r. o., Brno 2000, s 65
    4. Spinarova L,Toman J. Humoralni zmeny u chronickeho srdecniho selhani. Cor et Vasa 2001:43(10):5139
    5. Yanagisawa M, Kurihana H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:41115 Go to original source... Go to PubMed...
    6. Bartůněk L. Endoteliny a chronická srdeční insufi cience. Vnitřní Lékařství 2000; 46(1):5457
    7. Horký K. Patofyziologická úloha endotelinu u kardiovaskulárních onemocnění a moľnost jeho blokády. Remedia 1998; 8(6):408 416
    8. ©pinar J, Vítovec J, ©pinarová L, Toman J, Kubecová L, Pacher R, Stanek B, Wimmer A. The value of big endothelin level and hemodynamic variables in heart transplant candidates Cor et Vasa 2000; 42(10):495500
    9. Pacher R, Stanek B, Huelsman M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27(3):633641 Go to original source... Go to PubMed...
    10. ©pinarová L, Toman J, Pospíąilová J, et al. Humoral response in patients with chronic heart failure. Int J Cardiol 1998; 65:227232 Go to original source... Go to PubMed...
    11. Zukowska-Grojec Z, Marks ES, Haass M. Neuropeptide Y is a potent vasoconstrictor and a cardiodepresssant in rat. Am J Physiol 1987; 253:H 1234 Go to original source... Go to PubMed...
    12. Castellani S, Paladini B, Paniccia R, et al. Increased renal formation of thromboxane A2 and prostaglandin F2 alpha in heart failure. Am Heart J 1997; 133:94100 Go to original source... Go to PubMed...
    13. Wijnbenga AAM, Balk AHM, Jonkman FAM et al. Relation of atrial natriuretic peptides to left ventricular systolic and diastolic function in heart failure. Eur J Heart Failure 1999; 1:5158 Go to original source... Go to PubMed...
    14. Sudoh T, Kangawa K, Minamino N et al. A natriuretic peptide in porcine brain. Nature 1988; 332:7881 Go to original source... Go to PubMed...
    15. Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350:13491353 Go to original source... Go to PubMed...
    16. Vítovec J, ©pinarová L. Natriuretické peptidy-diagnostika a léčba. Remedia 2004;14(2):177181
    17. Oral I. Natriuretické peptidy současný stav klinického vyuľití jejich stanovení. Vnitřní Lék 2003; 49:521523
    18. Kalra PR, Anker SD, Struthers AD et al. The role of C type natriuretic peptide in cardiovascular medicine. Eur Heart J 2001; 22:9971007 Go to original source... Go to PubMed...
    19. Maisel AS, Krishnaswamy P et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis heart failure. N Eng J Med 2002; 347:161167 Go to original source... Go to PubMed...
    20. Spinar J, Vitovec J. Normy pro BNP a NT-pro BNP stanoveny. Cor et Vasa 2005;47(10):
    21. Hradec J. Mohou se stát natriuretické paptidy křią»álovou koulí kardiologa? JACC-CZ 2003; 5:255257
    22. Nieminen MS, Boehm M, Cowie MR et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005; 26:383416
    23. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2005; 26:11151140 Go to original source...
    24. Maisel A, McCord J, Nowak RM et al. Results from Breathing Not Properly Study (BNP). J Am Coll Cardiol 2003; 41:20102017 Go to original source...
    25. Januzzi LJ, Camargo CA, Anwarudin S et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. J Am Coll Cardiol 2005; 95:948954 Go to original source...
    26. Harjola VP, Siirla-Waris K, Peuhkurinen K et al: FINN-AKVA Finnish Acute Heart Failure study-Prognostic signifi cance of NTproBNP as early follow-up. Abstract Book proCardio Symposium, 3rd International Symposium on NT-proBNP,May 2728,2005, Dresden, Germany
    27. Bettencourt P, Azevedo A, Pimenta J et al. N-terminal-pro-Brain Natriuretic Peptide predicts outcome after hospital discharge in heart failure patients. Circ 2004; 110:21682174 Go to original source... Go to PubMed...
    28. Staněk V. Kardiologie a biochemie. Znamenají natriuretické peptidy novou éru v diagnostice a kontrole léčby srdečního selhání. Cor Vasa 2002; 44:504505
    29. ©pinarová L, Toman J, Meluzín J, Hude P, Krejčí J, Tomandl J, Vítovec J. Natriuretic peptides and myocardial function in chronic heart failure. Eur J Echocard 2003; 4:Suppl.1:S 34 Go to original source...
    30. Petrie MC, McClure SJ, Love MP, et al. Novel neuropeptide in the pathophysiology of heart failure; adrenomedullin and endothelin-1. Eur J Heart Failure 1999; 1:2529 Go to original source... Go to PubMed...
    31. Funaya H, Kitakaze M, Node K, et al. Plasma adenosine levels increase in patients with chronic heart failure. Circulation 1997; 95:13631365 Go to original source... Go to PubMed...
    32. Pěnička M, Gregor P. Hypotéza kardiovaskulárních onemocnění. Postgraduální medicína 1999; 1:3443
    33. Niebauer J. Inflammatory mediators in heart failure. Int J of Cardiology 2000; 72:209213 Go to original source... Go to PubMed...
    34. Paulus WJ. How are cytokines activated in heart failure? Eur J Heart Fail 1999; 1:309312 Go to original source... Go to PubMed...
    35. Francis SE, Holden H, Holt CM. et al. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1998; 30:215230 Go to original source... Go to PubMed...

    Return to the content